Breakthrough pain and rapid-onset opioids in patients with cancer pain: a narrative review.
Breakthrough pain
Cancer pain
Rapid-onset opioids
Journal
Journal of Yeungnam medical science
ISSN: 2799-8010
Titre abrégé: J Yeungnam Med Sci
Pays: Korea (South)
ID NLM: 9918333886606676
Informations de publication
Date de publication:
30 Jun 2023
30 Jun 2023
Historique:
received:
03
04
2023
accepted:
19
05
2023
medline:
10
7
2023
pubmed:
10
7
2023
entrez:
10
7
2023
Statut:
aheadofprint
Résumé
Breakthrough pain is transitory pain that occurs despite the use of opioids for background pain control. Breakthrough pain occurs in 40% to 80% of patients with cancer pain. Despite effective analgesic therapy, patients and their caregivers often feel that their pain is not sufficiently controlled. Therefore, an improved understanding of breakthrough pain and its management is essential for all physicians caring for patients with cancer. This article reviews the definition, clinical manifestations, accurate diagnostic strategies, and optimal treatment options for breakthrough pain in patients with cancer. This review focuses on the efficacy and safety of rapid-onset opioids, which are the primary rescue drugs for breakthrough pain.
Identifiants
pubmed: 37424088
pii: jyms.2023.00367
doi: 10.12701/jyms.2023.00367
doi:
Types de publication
Journal Article
Langues
eng